Arterial Thrombosis - Pipeline Review, H2 2020

September 2020 | 40 pages | ID: AADAEBD6B94EN
Global Markets Direct

Abstracts

Arterial Thrombosis - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis - Pipeline Review, H2 2020, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape.
Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, arterial thrombosis can cause several serious conditions, including stroke, heart attack and peripheral arterial disease (PAD). Predisposing factors include smoking, obesity, diabetes, hypertension and high cholesterol level. Treatment includes thrombolytic agents and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Arterial Thrombosis - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Arterial Thrombosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Arterial Thrombosis (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Arterial Thrombosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Arterial Thrombosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Arterial Thrombosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Arterial Thrombosis (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Arterial Thrombosis (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Arterial Thrombosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Arterial Thrombosis - Overview
Arterial Thrombosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Arterial Thrombosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Arterial Thrombosis - Companies Involved in Therapeutics Development
Anthos Therapeutics Inc
Astellas Pharma Inc
GLSynthesis Inc
Jiangsu Hengrui Medicine Co Ltd
MDI Therapeutics Inc
Oasis Pharmaceuticals LLC
Protheragen Inc
Arterial Thrombosis - Drug Profiles
abelacimab [INN] - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6537 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-409 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDI-2517 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OA-150 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-007867 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-2285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit NMMHC IIA for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Arterial Thrombosis - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Arterial Thrombosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Arterial Thrombosis - Pipeline by Anthos Therapeutics Inc, H2 2020
Arterial Thrombosis - Pipeline by Astellas Pharma Inc, H2 2020
Arterial Thrombosis - Pipeline by GLSynthesis Inc, H2 2020
Arterial Thrombosis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Arterial Thrombosis - Pipeline by MDI Therapeutics Inc, H2 2020
Arterial Thrombosis - Pipeline by Oasis Pharmaceuticals LLC, H2 2020
Arterial Thrombosis - Pipeline by Protheragen Inc, H2 2020
Arterial Thrombosis - Dormant Projects, H2 2020
Arterial Thrombosis - Dormant Projects, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Arterial Thrombosis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Anthos Therapeutics Inc
Astellas Pharma Inc
GLSynthesis Inc
Jiangsu Hengrui Medicine Co Ltd
MDI Therapeutics Inc
Oasis Pharmaceuticals LLC
Protheragen Inc